Attorneys For Onglyza Lawsuits Look To New Study Showing Risk For Acute Pancreatitis

Print

Onglyza Lawsuits Allege Astrazeneca Failed To Warn That Its Type 2 Diabetes Drugs May Cause Pancreatic Cancer And Pancreatitis.

onglyza-kombiglyze-lawsuit-Side-Effects-Lawyer-Past Onglyza studies have shown a link between the type 2 diabetes drug and and the potential heart failure. Attorneys at Wright & Schulte LLC, who are investigating Onglyza lawsuits, are now looking at a new study that has found patients who take Onglyza to treat type 2 diabetes are at risk for acute pancreatitis (inflammation of the pancreas). AstraZeneca manufacturers Onglyza (saxagliptin) and Kombiglyze XR (saxagliptin and metformin hydrochloride extended release). The diabetes drug manufacturers is currently facing Onglyza lawsuits are being filed alleging the company knew that its diabetes drug Onglyza has the potential to cause serious side effects such as heart failure, pancreatitis, pancreatic cancer and thyroid cancer but failed to warn doctors and their patients about the risks.

The attorneys at Wright & Schulte LL continue to investigate Onglyza lawsuits. If you believe you or someone you know has experienced heart failure, pancreatic cancer or thyroid cancer and have taken the prescription drug Onglyza or Kombiglyze XR contact one of the firms attorneys to discuss your legal recourse by calling 1-800-399-0795 or you can visit www.yourlegalhelp.com to fill out our contact form.

The meta-analysis included three clinical trials on cardiovascular outcomes and dipeptidyl peptidase-4 (DPP-4) drugs, including Onglyza. DPP-4 drugs block an enzyme in the body that reduces insulin production. Patients in each of the three trials were given either a placebo or DPP-4 drugs, including Onglyza (saxagliptin), Nesina (aloglptin) and Januvia (sitagliptin). Researchers discovered that patients who took the DPP-4 drugs had a higher rate of acute pancreatitis than patients who took a placebo. Additionally, rates of acute pancreatitis were similar in patients taking the DPP-4 drugs.
[newyork.legalexaminer.com/defective-dangerous-products/new-study-reports-increased-risk-of-pancreatitis-with-onglyza/, New York Legal Examiner, February 17, 2016]

This is not the first study claiming a link between pancreatitis and diabetes drugs. In June 2013, the British Medical Journal published an article of its investigation on the two main types of incretin mimetic drugs which help control blood glucose level – DDP-4, such as Onglyza, and glucagon-like peptide-1 (GLP-1). According to the article, the medical journal found unpublished data pointing to the drugs having “inflammatory pancreatic effects.” Additionally, the article mentioned a study published in the journal, Diabetes, in July 2013, in which researchers from UCLA and the University of Florida analyzed pancreases of human organ donors. Eight of the organ donors had type 2 diabetes and had been taking an incretin mimetic for at least a year. Twelve other diabetic organ donors had been taking other classes of treatment. Fourteen non-diabetic organ donors were used as controls. The researchers found the pancreases of those who had taken incretin mimetics were on average 40 percent larger, with more precancerous changes.
[rxisk.org/wp-content/uploads/2015/12/Cohen-Incretin-bmj.f3680.full_.pdf]

The attorneys at Wright & Schulte LLC continue to investigate Onglyza lawsuit claims and has spoken with people who were prescribed the type 2 diabetes drug and suffered heart failure, pancreatitis, pancreatic cancer, thyroid cancer or other serious side effects. To speak with one of the firm’s attorneys, contact Wright & Schulte by visiting www.yourlegalhelp.com or call 1-888-399-0795.

Onglyza (saxagliptin) was approved in 2009 by the U.S. Food and Drug Administration (FDA) and Kombiglyze XR (saxagliptin and metformin hydrochloride extended-release) was approved in 2010. The FDA launched an investigation into incretin mimetic drugs after reviewing a study published in Gastroenterology in July 2011 that used the agency’s adverse events database from 2004-2009 and found reports of pancreatitis, pancreatic cancer, and thyroid cancer in patients with type 2 diabetes. Incretin mimetic drugs work by mimicking the incretin hormones that the body usually produces naturally to stimulate the release of insulin after a meal.
[gastrojournal.org/article/S0016-5085(11)00172-7/ fulltext, Gastroenterology]

Wright & Schulte notes that AstraZeneca is facing Onglyza and Kombiglyze XR lawsuit claims that allege the type 2 diabetes drugs can potentially cause life-threatening side effects that include heart failure, pancreatitis, pancreatic cancer, thyroid cancer and other health complications.

About Wright & Schulte LLC and Filing An Onglyza Lawsuit:

Wright & Schulte LLC is an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright Schulte LLC stand up for the rights of people who have been injured or wronged, and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, do not hesitate to contact Wright & Schulte LLC today. Free Onglyza Lawsuit and Kombiglyze XR Lawsuit case evaluations are available through yourlegalhelp.com, or call 1-888-399-0795.

Contact:
Wright & Schulte LLC
865 S. Dixie Dr.
Vandalia, Ohio 45377
1-800-399-0795
http://www.yourlegalhelp.com

This entry was posted in Wright & Schulte Lawsuit News. Bookmark the permalink.